Expand Your Reach into the Plasma Proteome

Why Plasma?

Plasma is the most frequently investigated biological fluid in biomedical research mainly due to the easy access and the wealth of information it offers. Quantitative levels of selected plasma proteins can provide a snapshot of the health status of an individual and offer insights into disease onset or therapy response. These factors make plasma the model system of choice when investigating novel medical treatments and diagnostics.

Biognosys’ Plasma Proteomics Tools

Routine plasma proteomics applications are challenged by the complexity of the workflow, the low multiplexing possibilities, and the limited number of target proteins that can be accurately quantified. To that extent researchers are faced with many unanswered questions when it comes to plasma proteomics research.

To address the limitations of the existing tools, Biognosys' scientists have developed a portfolio of solutions for high-throughput and high-multiplexed quantification of human plasma proteins that cover a complete workflow from sample preparation to data analysis.

Best in class tools for plasma proteomics research

Ease of Use

Complete workflow from sample preparation to data analysis

Comprehensive Coverage

Protein target lists covering more than 500 plasma proteins for native and depleted plasma

Unmatched Multiplexing Capacity

Allowing the quantification of hundreds of proteins per plasma sample in one single run

Higher Throughput

Enabling the analysis of thousands of samples by seamless adaptation to automated liquid handling systems

Proven Technology

Based on cutting-edge discovery and targeted proteomics mass spectrometry technology developed in-house

Personalized Support

Biognosys scientists support you with establishing a complete work ow in your laboratory

Scientifically proven

Most recent examples of Biognosys proteomics technology in plasma research:

Mayr M. Plasma Proteomics in Epidemiology: are we measuring the correct apolipoproteins for cardiovascular disease risk assessment? Webinar, May 2017.

Pechlaner R, et al. Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):789-800.

Cantonwine DE, et al. Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth. Am J Obstet Gynecol. 2016 May;214(5):631.e1-631.e11.

Yin X, et al. Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates. Circ Cardiovasc Genet. 2017; 10(6).


Let us help you do great proteomics!

If you’re interested in learning more about our plasma proteomics tools, don’t hesitate to contact us. We would be pleased to schedule a meeting and support you with all of your proteomics needs.



Let us help you do great proteomics!

Please click here to contact us.